Open AccessA Combination Chemotherapy Protocol (VELCAP‐L) for Dogs with Lymphoma
Author(s) -
Zemann Barbara I.,
Moore Antony S.,
Rand William M.,
Mason Gail,
Ruslander David M.,
Frimberger Angela E.,
Wood Carrie A.,
L'Heureux Deborah A.,
Gliatto John,
Cotter Susan M.
Publication year - 1998
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.1998.tb02151.x
Subject(s) - medicine , vincristine , prednisone , cyclophosphamide , regimen , chemotherapy , lymphoma , canine lymphoma , complete remission , stage (stratigraphy) , spontaneous remission , gastroenterology , combination chemotherapy , doxorubicin , surgery , pathology , paleontology , alternative medicine , biology
Ninety‐eight dogs with lymphoma treated with a 5‐drug combination chemotherapy regimen (vincristine, L‐asparaginase. cyclophosphamide, doxorubicin, prednisone [VELCAP‐L]) were evaluated for pretreatment characteristics predictive for response and remission duration. The complete remission rate was 69%, with a median remission duration of 55 weeks. Dogs with advanced stage of disease, constitutional signs, dogs that were older, and dogs that were dyspneic were less likely to achieve remission. Once in remission, small dogs and dogs without pretreatment thrombocytopenia were likely to have longer remission duration. Toxicoses were frequent, but rarely fatal, and no predictitive factors were found for a dog developing toxicoses. VELCAP‐L is an effective treatment for dogs in stage I‐III lymphoma, particularly in young, small animals.